antibiotic/atrophy

TABLE OF CONTENTS 1. BACKGROUND OF THE INVENTION 1.1 TECHNICAL FIELD 1.2 BACKGROUND OF ART 2. SUMMARY OF THE INVENTION 3. BRIEF DESCRIPTION OF THE DRAWINGS 4. DESCRIPTION OF PREFERRED EMBODIMENTS 5. CLAIMS 6. ABSTRACT OF THE DISCLOSURE 7. DRAWING 8. DECLARATION AND POWER OF ATTORNEY 9. DECLARATION

TABLE OF CONTENTS 1. BACKGROUND OF THE INVENTION 1.1 TECHNICAL FIELD 1.2 BACKGROUND OF ART 2. SUMMARY OF THE INVENTION 3. BRIEF DESCRIPTION OF THE DRAWINGS 4. DESCRIPTION OF PREFERRED EMBODIMENTS 5. CLAIMS 6. ABSTRACT OF THE DISCLOSURE 7. DRAWING 8. DECLARATION AND POWER OF ATTORNEY 9. DECLARATION

BACKGROUND OF THE INVENTION 1) Field of the Invention The present invention relates to novel lactic acid bacteria belonging to the genus Streptococcus salivarius subsp. thermophilus and variants thereof. This invention is also concerned with a novel antibacterial substance produced by the above

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel lactic acid bacteria belonging to the genus Streptococcus salivarius subsp. thermophilus and variants thereof. This invention is also concerned with a novel antibacterial substance produced by the above

BACKGROUND OF INVENTION It is currently believed that the diseases known as "autoimmune" diseases are caused by the body's immune system attacking the body itself. But I have discovered that these so-called "autoimmune" diseases are actually caused by stealthy intra-cellular bacteria. I have

FIELD OF THE INVENTION This invention relates to the field of protein engineering. Specifically, this invention relates to a directed evolution method for preparing a polynucleotide encoding a polypeptide. More specifically, this invention relates to a method of using mutagenesis to generate a novel

FIELD OF THE INVENTION This invention relates to the field of protein engineering. Specifically, this invention relates to a directed evolution method for preparing a polynucleotide encoding a polypeptide. More specifically, this invention relates to a method of using mutagenesis to generate a novel

FIELD OF THE INVENTION The present invention relates to a dental composition containing an organic nanotube. More specifically, the present invention relates to a dental composition comprising: unsaturated double bond-containing monomers and/or oligomers; a catalytic amount of polymerization

BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to a method for delivery of compositions to the ocular tissues and, more particularly, to a method for delivering compositions to the ocular tissues in sufficient quantity without toxic effects. Description of the

FIELD OF THE INVENTION The present invention relates to a composite semipermeable membrane having a skin layer which includes a polyamide resin and a porous support that supports the skin layer, and to a process for producing the composite semipermeable membrane. The composite semipermeable

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to methods and pharmaceutical compositions for administering therapeutic cells to the upper third of the nasal cavity of a mammal, thereby enabling the therapeutic cells to bypass the blood-brain barrier to

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is directed to methods and pharmaceutical compositions for administering therapeutic cells to the upper third of the nasal cavity of a mammal, thereby enabling the therapeutic cells to bypass the blood-brain barrier to

BACKGROUND OF THE INVENTION R. Battisti, et al., U.S. Pat. No. 4,149,005 (Apr. 10, 1979) discloses compounds of the formula: ##STR1## where R is H or CH.sub.3, X is H, Br, Cl, alkyl, alkoxy or carboxyalkyl groups with from 1 to 4 carbon atoms or CF.sub.3 ; and n is 1 or 2. These are disclosed as

PRIOR ART 1. R. Battisti, et. al., U.S. Pat. No. 4,149,005 (Apr. 10, 1979) discloses compounds of the formula: ##STR1## where R is H or CH.sub.3, X is H, Br, Cl, alkyl, alkoxy or carboxyalkyl groups with from 1 to 4 carbon atoms or CF.sub.3 ; and n is 1 or 2. These are disclosed as being used as

PRIOR ART 1. R. Battisti, et. al., U.S. Pat. No. 4,149,005 (Apr. 10, 1979) discloses compounds of the formula: ##STR1## where R is H or CH.sub.3, X is H, Br, Cl, alkyl, alkoxy or carboxyalkyl groups with from 1 to 4 carbon atoms or CF.sub.3 ; and n is 1 or 2. These are disclosed as being used as